CMSC

TG Therapeutics Announces Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting

Retrieved on: 
Freitag, Mai 31, 2024
Patient, CMSC, Therapy, Multiple sclerosis, MD, RMS, Publication, Harbor

NEW YORK, May 31, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting.

Key Points: 
  • NEW YORK, May 31, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting.
  • Presentations are now public and can be viewed using the below links.
  • of California San Francisco, San Francisco, CA
    Lead Author: Riley Bove, MD - UCSF Weill Institute of Neurosciences, Dept.
  • of California San Francisco, San Francisco, CA
    Presentations are available on the Publications page, located within the Pipeline section, of the Company’s website at https://www.tgtherapeutics.com/publications/ .

Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research

Retrieved on: 
Donnerstag, Mai 30, 2024
Patient, CMSC, Organization, Mass, Mass General Brigham, Tiziana, Foralumab, FDA, DSM-IV codes, Multiple sclerosis, Cone Health Women's Hospital, Research, Neurology, Fatigue, Multiple sclerosis research, Hospital, MFIS, Pharmaceutical industry

The award ceremony will take place on May 30, 2024 at the Consortium of Multiple Sclerosis Centers annual meeting being held in Nashville, Tennessee.

Key Points: 
  • The award ceremony will take place on May 30, 2024 at the Consortium of Multiple Sclerosis Centers annual meeting being held in Nashville, Tennessee.
  • “We are thrilled to see Dr. Howard Weiner recognized with the ‘Giants of MS’ award for his exceptional achievements in MS research,” said Gabriele Cerrone, Chairman, acting CEO, and founder of Tiziana Life Sciences.
  • Weiner's relentless pursuit of scientific excellence and commitment to improving patient outcomes also exemplifies the values we uphold at Tiziana.
  • This award acknowledges individuals who have demonstrated extraordinary leadership and innovation in the field of MS research.

TG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting

Retrieved on: 
Dienstag, Mai 28, 2024
Patient, CMSC, Abstract (summary), Therapy, Multiple sclerosis, MD, RMS, Publication, Harbor

NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, being held May 29 – June 1, 2024, in Nashville, Tennessee.

Key Points: 
  • NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, being held May 29 – June 1, 2024, in Nashville, Tennessee.
  • Abstracts are now available online and can be accessed on the CMSC meeting website at www.mscare.org/2024 or by clicking on the following link: https://meridian.allenpress.com/ijmsc/article/26/s1/1/500896/Abstracts-f... .
  • of California San Francisco, San Francisco, CA
    Lead Author: Riley Bove, MD - UCSF Weill Institute of Neurosciences, Dept.
  • of California San Francisco, San Francisco, CA
    Presentations will be available on the Publications page, located within the Pipeline section, of the Company’s website at https://www.tgtherapeutics.com/publications/ .

New Pilot Study Using the FDA-Cleared Cionic Neural Sleeve Demonstrates Significant Improvements to Gait Impairments for Patients with Multiple Sclerosis

Retrieved on: 
Dienstag, Mai 28, 2024
Apps, Applications, Technology, Mobile, Wireless, Medical Devices, FDA, Health Technology, Software, Health, Data Management, CMSC, Doctor of Philosophy, Ankle, Foot, Bionics, Outline of health sciences, Movement, Canadian International Council, Cleveland State University, Neurotechnology, Walking, Pharmaceutical industry

CIONIC , the neurotech inventor pioneering bionic clothing, today announced data showcasing the impact of the FDA-cleared Cionic Neural Sleeve as assistive technology for individuals experiencing difficulty walking due to multiple sclerosis (MS).

Key Points: 
  • CIONIC , the neurotech inventor pioneering bionic clothing, today announced data showcasing the impact of the FDA-cleared Cionic Neural Sleeve as assistive technology for individuals experiencing difficulty walking due to multiple sclerosis (MS).
  • The real-world study, “Impact of the Cionic Neural Sleeve on Ankle Kinematics during Gait in Multiple Sclerosis,” evaluated the impact of CIONIC’s proprietary array-based stimulation approach to address neuromuscular walking challenges associated with foot drop, one of the most common gait impairments for individuals with neurologic conditions.
  • Results of the study demonstrated significant improvements for both measures, and all participants experienced improvements to dorsiflexion at heel strike and reductions in inversion during swing when functional electrical stimulation from the Cionic Neural Sleeve activated the affected muscles.
  • “These results show the tremendous power of our software-steered neuromodulation array and real-time adaptive algorithms to improve walking for individuals with MS.”
    To learn more about the Cionic Neural Sleeve, visit cionic.com .

Helius Medical Technologies to Exhibit at 2024 CMSC Annual Meeting, Marking a Year of Achievements: Making PoNS More Available to People with MS

Retrieved on: 
Donnerstag, Mai 23, 2024
Music City Center, CMSC, Health care, Negotiation, Therapy, CMS, Medicare, HCPCS, News, Pons, Gait, Multiple sclerosis, HSDT, Helios, Excellence, Annual general meeting, Health insurance

CMSC’s 38th Annual Meeting runs from May 29 to June 1 at the Music City Center in Nashville, TN.

Key Points: 
  • CMSC’s 38th Annual Meeting runs from May 29 to June 1 at the Music City Center in Nashville, TN.
  • “From the beginning, we have prioritized getting PoNS to as many people with MS and gait deficit as possible.
  • Helius also has trained a critical mass of physical therapists, who design the customized exercise regimens that are an integral part of PoNS Therapy®.
  • Removing those barriers and helping more people benefit from PoNS has been our goal since the start.”

Ashvattha Therapeutics to Present Preclinical Data at the CMSC and SNMMI Annual Meetings

Retrieved on: 
Donnerstag, Mai 23, 2024
PET, Molecular imaging, CMSC, Stanford University, Therapy, CSF1R, Society, Nanomedicine, Inflammation, EAE

REDWOOD CITY, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, today announced that the company will present preclinical data at the upcoming Consortium of Multiple Sclerosis Centers (CMSC) and Society of Nuclear Medicine & Molecular Imaging 2024 annual meetings.

Key Points: 
  • REDWOOD CITY, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, today announced that the company will present preclinical data at the upcoming Consortium of Multiple Sclerosis Centers (CMSC) and Society of Nuclear Medicine & Molecular Imaging 2024 annual meetings.
  • The presentations will demonstrate the therapeutic potential of Ashvattha’s novel CSF1R dendranib for MS, based on symptom reduction in a mouse experimental autoimmune encephalitis (EAE) model of MS. Additionally, the presentation by Ashvattha’s collaborators at Stanford University will demonstrate reduction in neuroinflammation following CSF1R dendranib treatment by PET imaging using Ashvattha’s proprietary 18F-OP-801 radioimaging agent.
  • Details for the presentations are as follows:
    May 29 – June 1, 2024

EQS-News: Immunic to Participate in Investor and Scientific Conferences in May

Retrieved on: 
Freitag, Mai 10, 2024
Assistant professor, AFL, Research, Cleveland Clinic, Serum, Coeliac disease, Psychiatry, Multiple sclerosis, Communication, DDW, SIRT6, Annual general meeting, CMSC, Biotechnology, Pharmaceutical industry

NEW YORK, May 6, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in May:

Key Points: 
  • NEW YORK, May 6, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in May:
    May 12-14 and 21-22: Bio€quity Europe 2024.
  • Jessica Breu, Vice President Investor Relations and Communications at Immunic, will attend and host one-on-one investor meetings at this conference taking place in San Sebastián, Spain and virtually.
  • To schedule a meeting, please use the Bio€quity conference portal or contact Jessica Breu at: [email protected] .
  • Presentation Title: Impact of Vidofludimus Calcium (VidoCa) on Serum Neurofilament Light Chain (NfL) Levels in Patients with Progressive Multiple Sclerosis: Interim Data from the CALLIPER Trial

Dr. Ahmed Z. Obeidat Named Finalist for the 2024 "CMSC Neuroinnovator of the Year"

Retrieved on: 
Montag, Mai 6, 2024
Dementia, Prevalence, Dermatology, Cognition, Thought, Research, Light, Background, Patient, Fatigue, Psoriasis, Biomarker, Light therapy, Walking, CMSC, Medical college, Pharmaceutical industry

"This trial targets the biggest unmet need in MS, which is fatigue and the cognitive difficulties associated with it. The trial will be able to detect changes in improved fatigue, stabilization, and maybe even improve cognition," said Dr. Obeidat. "I think the inclusive target patient population within the Silent Symptoms trial will change our thinking about who should be enrolled in clinical trials. Most trials have been very selective -- excluding people who are not walking, or are over age 60, and so on. The Silent Symptoms trial will go all in, taking any MS patient with fatigue, which is the vast majority of our patients, and offering them phototherapy lights that they can take home."

Key Points: 
  • The recognition highlights the groundbreaking work and innovative approach sponsored by Cytokind, Inc. in addressing unmet needs in MS treatment.
  • The trial will be able to detect changes in improved fatigue, stabilization, and maybe even improve cognition," said Dr. Obeidat.
  • The 2024 CMSC Neuroinnovation Competition aims to recognize and celebrate original and innovative work in the field of MS research.
  • The finalists will present their ideas at the annual CMSC conference in Nashville, Tennessee, from May 29 to June 1.

TG Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results

Retrieved on: 
Dienstag, August 1, 2023
CMS, SG, Centers for Medicare & Medicaid Services, Conference call, CD20, Clinical trial, Prescription, Finance, Multiple sclerosis, TG, CMSC, Sale, II, Medicare, RMS, Acquisition, Patient, Physician, R, FDA, EC, Therapy, Conference, Food, European Commission, D, Video game, Pharmaceutical industry, Health insurance, Clothing, Cryptocurrency

Michael S. Weiss, the Company's Chairman and Chief Executive Officer, stated, “We are pleased to report our second quarter 2023 results, representing our first full quarter of BRIUMVI sales, which exceeded our expectations.

Key Points: 
  • Michael S. Weiss, the Company's Chairman and Chief Executive Officer, stated, “We are pleased to report our second quarter 2023 results, representing our first full quarter of BRIUMVI sales, which exceeded our expectations.
  • Achieved $16 million in BRIUMVI net sales for the second quarter 2023, total net product revenue of $23.8 million since launch.
  • Cash Position and Financial Guidance: Cash, cash equivalents and investment securities were $144.9 million as of June 30, 2023.
  • The Company will host a conference call today, August 1, 2023, at 8:30 AM ET, to discuss the Company’s financial results from the second quarter, ended June 30, 2023, the Neuraxpharm ex-U.S. commercialization agreement, and provide a business outlook for the remainder of 2023.

TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting

Retrieved on: 
Freitag, Juni 2, 2023
Publication, Multiple sclerosis, TG, CMSC, II, RMS, Public, Patient, Therapy, Pharmaceutical industry, Fatigue

NEW YORK, June 02, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the Consortium of Multiple Sclerosis Centers (CMSC) annual meeting.

Key Points: 
  • NEW YORK, June 02, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the Consortium of Multiple Sclerosis Centers (CMSC) annual meeting.
  • A link to the oral presentation is included below.
  • Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics stated, “We were excited to present additional analyses from the ULTIMATE I & II Phase 3 trails last night at the CMSC annual meeting.
  • We believe the data continue to support the unique attributes of BRIUMVI and we look forward to continuing to present additional data at medical meetings throughout the year.”
    Oral Presentation: Ublituximab Is Associated with Significant Improvement in Fatigue: Results from Ultimate I and II
    The data presentation is also available on the Publications page, located within the Pipeline section, of the Company’s website at www.tgtherapeutics.com/publications.cfm.